A Phase 1/2 interventional study of Mechanically Engineered Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes and Umbilical cord mesenchymal stem cell-derived exosomes in Thin Endometrial Lining, Female Infertility and Intrauterine Adhesions, sponsored by Tang-Du Hospital. Recruiting at 2 sites in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-03-26.
Sponsored by Tang-Du Hospital · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Infertility, Female with a site in China — 17 open to participants now, 20 under way, 1 of them phase 3. Infertility, Female · China.
Among the 58 studies in Infertility, Female with a site in China, this one is the 39th largest by planned enrollment of the 51 interventional ones that give a count, is one of 7 that started in 2025, is the only one in phase 1/2, reaches primary completion later than 3 of the 19 other live ones, and was the 52nd registered.
553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.
Browse Infertility, Female studies →17 of the 58 studies in Infertility, Female with a site in China are open now. Recruiting first, the newest first:
Peking University Third Hospital · Sites in China
Ages 18–40 · Women only
Shandong University of Traditional Chinese Medicine · Sites in China
Ages 21–44 · Women only
Suzhou Centergene Pharmaceuticals Co.,Ltd. · Sites in China
Ages 20–40 · Women only · Healthy volunteers
Peking University Third Hospital · Sites in China
Ages 18+
Nanjing University · Sites in China
Ages 20–37 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.
This study: 20 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 1 · Phase 3 6 · Phase 4 4
First in 2014; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is close to the median of 100 across 378 interventional studies indexed under Infertility, Female.
Median enrollment 178 across the 51 interventional studies, 2,569 across the 7 observational. Of the 19 that completed or were terminated, 3 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 58 have an industry lead sponsor. The 10 most frequent:
Tang-Du Hospital is the lead sponsor of 167 studies on the registry; 78 are open to participants now.
Tang-Du Hospital has 1 study filed under Infertility, Female — fewer than ten, so there is no comparison to draw.
4 of the studies in Infertility, Female with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06644794Phase 3Shandong University of Traditional Chinese MedicineProgesterone-modified Natural Cycle for FET | 2027-09-10 |
| NCT06775093Peking University Third HospitalEffects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity | 2026-12-31 |
| NCT06020924Wenwen WangThe Effects of Uterine Fibroids on Pregnancy in Women | 2026-12-31 |
| NCT07409792Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical UniversityMultifaceted Benefits of Auricular Point Sticking for IVF Patients: Psychological Well-being, Sleep, and Treatment Outcomes | 2027-01-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 58 studies in Infertility, Female with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate if engineered mechanically umbilical cord-derived stem cell exosomes, or conventional umbilical cord -derived stem cell exosomes, can improve endometrial thickness in women with thin endometrium.
The main questions it aims to answer are:
Can exosomes delivered via subendometrial injection improve endometrial thickness or clinical pregnancy rates compared to PRP (platelet-rich plasma)? Are there significant differences in endometrial thickness between the two treatment groups? Researchers will compare the intervention groups, which one group receives mechanical exosomes and the other receives conventional esosomes via subendometrial injection, to the control group, which receives PRP via the same methods, to see if exosomes provide superior therapeutic effects.
Participants will:
Receive either mechanical exosomesor or conventional esosomes or PRP through subendometrial injection.
Be monitored for changes in endometrial parameters.
This study is a prospective, non-randomized controlled clinical trial designed to evaluate the efficacy and safety of mechanically engineered umbilical cord mesenchymal stem cell-derived exosomes (ME-UCMSC-Exo) and conventional umbilical cord mesenchymal stem cell-derived exosomes (UCMSC-Exo) in the treatment of thin endometrium secondary to severe intrauterine adhesions (IUA) following hysteroscopic adhesiolysis. Thin endometrium is a significant challenge in reproductive medicine, associated with poor embryo implantation rates, recurrent implantation failure (RIF), and increased risk of pregnancy complications. Despite conventional hormonal therapies, effective endometrial regeneration remains a clinical challenge.
Emerging regenerative therapies, including exosome-based interventions, offer promising avenues for enhancing endometrial repair and pregnancy outcomes. Exosomes, extracellular vesicles secreted by stem cells, play a crucial role in tissue regeneration by delivering bioactive molecules such as proteins, microRNAs (miRNAs), and growth factors to target cells. The study aims to determine whether mechanically engineered exosomes, which leverage biophysical modulation during the culture process, demonstrate superior efficacy compared to conventional exosomes and platelet-rich plasma (PRP), a widely used biological intervention for thin endometrium.
Study Design This is a prospective, non-randomized, parallel-controlled study.
Patients will be divided into three groups:
Control Group (PRP Group): Endometrial injection of autologous platelet-rich plasma (PRP).
Conventional Exosome Group: Endometrial injection of UCMSC-derived exosomes. Mechanically Engineered Exosome Group: Endometrial injection of ME-UCMSC-derived exosomes.
Primary endpoint: Change in endometrial thickness. Secondary endpoints: Clinical pregnancy rate, implantation rate, live birth rate, miscarriage rate, and safety assessments (including hypersensitivity reactions, infection, and long-term complications).
Intervention Details Each participant will receive a single intra-endometrial injection using a hysteroscopic-guided 17G needle during the proliferative phase (D3-D7 of the menstrual cycle).
PRP Group: 1-1.5mL PRP per injection site (autologous). UCMSC-Exo Group: 1-1.5mL conventional exosome solution per site. ME-UCMSC-Exo Group: 1-1.5mL mechanically engineered exosome solution per site. Rationale for PRP as a Positive Control PRP is used as a positive control due to its established efficacy in improving endometrial thickness and pregnancy outcomes. Meta-analyses of RCTs have demonstrated that PRP significantly enhances endometrial thickness (MD: 1.23mm, 95% CI: 0.87-1.59, p=0.000) and improves clinical pregnancy rates (RR: 2.04, 95% CI: 1.52-2.76, p=0.000). Additionally, PRP is autologous, safe, and widely used in reproductive medicine, making it a suitable comparative intervention for evaluating the therapeutic efficacy of exosomes.
Eligibility Criteria
Inclusion Criteria:
Exclusion Criteria:
Statistical Considerations \& Sample Size Estimated sample size: 90 patients (30 per group). Primary outcome variable: Endometrial thickness increase post-treatment. Sample size calculation based on ANOVA analysis and post-hoc Tukey HSD test to compare all intergroup differences while controlling the familywise error rate at α=0.05.
Considering a 10% dropout rate, a total of 90 patients will be recruited.
Follow-up and Outcome Assessment
Patients will be monitored at multiple time points:
Short-term efficacy evaluations:
Day of progesterone (P) transformation P+7 days Next embryo transfer cycle (HCG trigger day / FET cycle day of progesterone start).
Pregnancy outcomes:
Biochemical pregnancy (Day 15 post-ET). Clinical pregnancy confirmation (Week 5-6). Live birth rate and perinatal complications (up to 1 year post-intervention).
Safety evaluations:
Scientific \& Clinical Significance This is the first clinical study evaluating mechanically engineered and conventional umbilical cord-derived stem cell exosome therapy for thin endometrium.
If successful, the study will establish a novel, cell-free regenerative therapy for patients with refractory thin endometrium.
Findings could pave the way for future exosome-based treatments in reproductive medicine, expanding therapeutic options for women with uterine factor infertility.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive hysteroscopically guided intra-endometrial injection of 1-1.5 mL mechanically engineered umbilical cord mesenchymal stem cell-derived exosomes (ME-UCMSC-Exo) containing approximately 5×10¹⁰ particles/mL during the proliferative phase (Day 3-7 of the menstrual cycle). The exosomes are obtained from mechanically preconditioned UC-MSC cultures, which are subjected to biomechanical stress during expansion to enhance regenerative properties. The study aims to evaluate the efficacy of ME-UCMSC-Exo in improving endometrial thickness and pregnancy outcomes in patients with thin endometrium secondary to intrauterine adhesions.
Biological: Mechanically Engineered Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes
Participants in this arm will receive hysteroscopically guided intra-endometrial injection of 1-1.5 mL conventional umbilical cord mesenchymal stem cell-derived exosomes (UCMSC-Exo) containing approximately 5×10¹⁰ particles/mL during the proliferative phase (Day 3-7 of the menstrual cycle). Unlike the ME-UCMSC-Exo group, these exosomes are obtained from standard UC-MSC cultures without mechanical stress preconditioning. This group serves as a comparator to determine whether mechanical preconditioning enhances exosome efficacy in endometrial regeneration and pregnancy outcomes.
Biological: Umbilical cord mesenchymal stem cell-derived exosomes
Participants in this arm will receive hysteroscopically guided intra-endometrial injection of 1-1.5 mL autologous PRP following standard PRP preparation protocols during the proliferative phase (Day 3-7 of the menstrual cycle). PRP contains growth factors such as platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and transforming growth factor-beta (TGF-β), which have been shown to improve endometrial receptivity and pregnancy outcomes. This group serves as a positive control for assessing the efficacy of exosome-based therapies.
Biological: platelet-rich plasma
Mechanically engineered umbilical cord mesenchymal stem cell-derived exosomes (ME-UCMSC-Exo) are isolated from umbilical cord-derived mesenchymal stem cells (UCMSCs) subjected to mechanical stress conditioning during in vitro expansion. This process enhances exosome yield, bioactivity, and regenerative capacity. The exosomes are purified via ultracentrifugation and characterized for size, protein markers, and RNA content. In this study, ME-UCMSC-Exo is administered via intra-endometrial injection under hysteroscopic guidance. Each participant in this intervention group will receive 1-1.5 mL of exosome solution (containing approximately5\*10\^10 particles/mL) per injection site during the proliferative phase (Day 3-7 of the menstrual cycle). The aim is to enhance endometrial thickness, receptivity, and pregnancy outcomes in patients with thin endometrium secondary to intrauterine adhesions.
Also known as: ME-UCMSC-Exo, RH-Exo
Umbilical cord mesenchymal stem cell-derived exosomes (UCMSC-Exo) are obtained from standard cultured UCMSCs without mechanical stress preconditioning. These exosomes undergo identical purification and characterization procedures as ME-UCMSC-Exo but lack biomechanical priming. UCMSC-Exo is also administered intra-endometrially via hysteroscopic injection at a dose of 1-1.5 mL (5\*10\^10 particles/mL) per site.
Also known as: UCMSC-Exo, TCP-Exo
Platelet-rich plasma (PRP) is an autologous biological preparation obtained from centrifuged whole blood. It contains a high concentration of growth factors, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF), which promote endometrial regeneration. In this study, PRP will be administered via hysteroscopically guided intra-endometrial injection at a dose of 1-1.5 mL per injection site, following standard PRP preparation protocols. This group serves as a positive control for evaluating the efficacy of exosome-based therapies.
Also known as: PRP
Endometrial thickness
The endometrial thickness under ultrasound is measured on the HCG trigger day, oocyte retrieval day, day of progesterone Initiationor or embryo transfer day using transvaginal ultrasound in the sagittal/long-axis plane of the uterus. The measurement is taken at the thickest point within a 1 cm range from the uterine fundus, from the basal membrane on one side, perpendicular across the endometrial cavity line to the basal membrane on the opposite side.
Time frame: 30-90days
clinical pregnancy
A clinical pregnancy is diagnosed based on the presence of ultrasound confirmation of a gestational sac in the uterus.
Time frame: 1-6 months
Plan to share: Yes — Data on primary outcome measures, including endometrial thickness and pregnancy rates, will be shared after study completion. Requests for data access can be made through the corresponding author or institutional repository.
Supporting information: Clinical study report
Time frame: Individual participant data will be available upon request starting 6 months after the publication of study results and will remain accessible for 3 years.
Access criteria: Data access is limited to researchers conducting studies on endometrial regeneration and reproductive medicine. Researchers must submit a proposal detailing their intended data use. Approved applicants will receive access via a secure, password-protected platform under a formal data use agreement (DUA)
Started Feb 2025 (actual). Primary completion is estimated for Jun 2025, 3 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.